Ocrevus/ocrelizumab vs Kesimpta

Ocrevus (ocrelizumab) is indicated for the treatment of patients with relapsing forms of multiple sclerosis (RMS). Regulatory review documents for Ocrevus reported a 46% reduction in relapse rate compared to Rebif. Kesimpta is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Regulatory review documents for Kesimpta reported an Annualized Relapse Rate (ARR) reduction of 58.5%.

These drugs were studied in separate clinical trials with distinct designs, patient populations, and timepoints. Ocrevus's review cited a relapse rate of 0.16 for ocrelizumab versus 0.29 for Rebif, and a 40% reduction in disability progression events compared to Rebif. Kesimpta's review noted a 97.5% reduction for T1 GdE Lesions and a 34.4% reduction in 3-month confirmed disability worsening. The trials utilized different comparators and measured outcomes over varying periods.

It is crucial to understand that the figures presented for Ocrevus and Kesimpta are derived from their respective independent trials and are not head-to-head comparisons. Therefore, these figures should not be used to infer superiority of one drug over the other.